The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
6-fluoro-4-[7-[4-(4-isopropylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyridin-3-yl]-2-methyl-quinoline ID: ALA4778527
PubChem CID: 139326550
Max Phase: Preclinical
Molecular Formula: C30H30FN5
Molecular Weight: 479.60
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: Cc1cc(-c2cnc3cc(-c4ccc(N5CCN(C(C)C)CC5)cc4)ccn23)c2cc(F)ccc2n1
Standard InChI: InChI=1S/C30H30FN5/c1-20(2)34-12-14-35(15-13-34)25-7-4-22(5-8-25)23-10-11-36-29(19-32-30(36)17-23)27-16-21(3)33-28-9-6-24(31)18-26(27)28/h4-11,16-20H,12-15H2,1-3H3
Standard InChI Key: KNPAYODHVLRPPC-UHFFFAOYSA-N
Molfile:
RDKit 2D
36 41 0 0 0 0 0 0 0 0999 V2000
9.1913 -23.0217 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.1913 -23.8430 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.9007 -24.2516 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.9007 -22.6090 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.6060 -23.0217 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.6060 -23.8395 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
11.3840 -24.0910 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.8665 -23.4327 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.3840 -22.7703 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
8.4807 -22.6173 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.4796 -21.7948 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.7675 -21.3843 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.0558 -21.7991 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.0609 -22.6247 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.7736 -23.0274 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.3423 -21.3894 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
6.3393 -20.5649 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.6298 -20.1594 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.9215 -20.5676 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.9230 -21.3898 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.6329 -21.8040 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.3788 -24.9078 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.6665 -25.3099 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.6610 -26.1259 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.3663 -26.5397 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
12.0807 -25.3166 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.0779 -26.1277 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.7777 -26.5339 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.4809 -26.1302 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.4798 -25.3160 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.7793 -24.9135 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.9505 -26.5297 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.1868 -24.9062 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
4.2136 -20.1593 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.2132 -19.3421 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.5060 -20.5682 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
1 4 2 0
2 3 2 0
3 6 1 0
5 4 1 0
5 6 1 0
6 7 1 0
7 8 2 0
8 9 1 0
9 5 2 0
10 11 2 0
11 12 1 0
12 13 2 0
13 14 1 0
14 15 2 0
15 10 1 0
1 10 1 0
13 16 1 0
16 17 1 0
16 21 1 0
17 18 1 0
18 19 1 0
19 20 1 0
20 21 1 0
7 22 1 0
22 23 2 0
23 24 1 0
24 25 2 0
25 27 1 0
26 22 1 0
26 27 1 0
27 28 2 0
28 29 1 0
29 30 2 0
30 31 1 0
31 26 2 0
24 32 1 0
30 33 1 0
19 34 1 0
34 35 1 0
34 36 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 479.60Molecular Weight (Monoisotopic): 479.2485AlogP: 6.19#Rotatable Bonds: 4Polar Surface Area: 36.67Molecular Species: NEUTRALHBA: 5HBD: ┄#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): ┄#RO5 Violations (Lipinski): 1CX Acidic pKa: ┄CX Basic pKa: 8.42CX LogP: 5.13CX LogD: 4.07Aromatic Rings: 5Heavy Atoms: 36QED Weighted: 0.31Np Likeness Score: -1.50
References 1. Engers DW,Bollinger SR,Felts AS,Vadukoot AK,Williams CH,Blobaum AL,Lindsley CW,Hong CC,Hopkins CR. (2020) Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors., 30 (18): [PMID:32750526 ] [10.1016/j.bmcl.2020.127418 ]